Showing 1401-1410 of 1635 results for "".
- Bausch Health Announces Vyzulta is Now Approved In Brazilhttps://modernod.com/news/bausch-health-announces-vyzulta-is-now-approved-in-brazil/2479084/Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária). Vyzulta is indicated for the reduction of IOP in pa
- NEI Joins Call for Standardization of Ophthalmic Imaging Deviceshttps://modernod.com/news/nei-joins-call-for-standardization-of-ophthalmic-imaging-devices/2479064/The National Eye Institute (NEI), part of the National Institutes of Health, is joining the American Academy of Ophthalmology (AAO) and others in calling for imaging device makers to standardize their data formatting. Such standardization is expected to enable comm
- Neurophth Announces IND Approval in China for Leber Hereditary Optic Neuropathy Gene Therapyhttps://modernod.com/news/neurophth-announces-ind-approval-in-china-for-leber-hereditary-optic-neuropathy-gene-therapy/2479055/Neurophth Biotechnology announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the company’s investigational new drug (IND) application of NR082 (recombinant adeno-associated virus serotype 2 carrying ND4 gene; rAAV2-ND
- Nursing Homes See 96 Percent Decline In COVID Cases Since Vaccine Rollouthttps://modernod.com/news/nursing-homes-see-96-percent-decline-in-covid-cases-since-vaccine-rollout/2479027/The American Health Care Association and National Center for Assisted Living (AHCA/NCAL), which represents more than 14,000 nursing homes and long term care facilities across the US, released a
- NeurOptics Launches Pupillometry Program at Vanderbilt University Medical Centerhttps://modernod.com/news/neuroptics-launches-pupillometry-program-at-vanderbilt-university-medical-center/2479015/NeurOptics recently announced that its NPi-200 pupillometers and the Neurological Pupil Index (NPi) are now being used in the Neurological Intensive Care Unit at Vanderbilt University Medical Center, in Nashville, Tennessee, as an important measurement for managing patients with brain injury.
- Rabb-Venable Excellence in Ophthalmology Program Abstract Submission Open Until March 31https://modernod.com/news/rabb-venable-excellence-in-ophthalmology-program-abstract-submission-open-until-march-31/2478981/Each year, the National Medical Association–Ophthalmology Section sponsors the Rabb-Venable Excellence in Ophthalmology Program, which is committed to increasing diversity in eye care to better reflect the U.S. population. The Rabb-Venable Program encourages and fosters interest in ophthal
- EMA Continues Safety Probe of AstraZeneca’s COVID-19 Vaccine as More Countries Halt Usehttps://modernod.com/news/ema-continues-safety-probe-of-astrazenecas-covid-19-vaccine-as-more-countries-halt-use/2478974/The European Medicines Agency (EMA) said it continues to investigate a number of thromboembolic events in people administered AstraZeneca’s COVID-19 vaccine AZD1222, whilst continuing to back the benefits of the immunization. The probe comes as a number of major EU nations, including France
- NIH-Led Team Sets New Bar in Retinal Imaginghttps://modernod.com/news/nih-led-team-sets-new-bar-in-retinal-imaging/2478963/A team led by scientists at the National Eye Institute (NEI) has noninvasively visualized the light-sensing cells in the back of the eye, known as photoreceptors, in greater detail than ever before. Published in Optica, the researchers report how they improved imaging resolution by a thi
- Researchers Develop New Noninvasive Technique to Image Human Eyehttps://modernod.com/news/researchers-develop-new-noninvasive-technique-to-image-human-eye/2478947/Researchers have developed a noninvasive technique that can capture images of rod and cone photoreceptors with unprecedented detail. The advance could lead to new treatments and earlier detection for retinal diseases such as macular degeneration, according to a National Eye Institute news release
- Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patientshttps://modernod.com/news/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients/2478948/Alteogen announced that it has completed phase 1 clinical trial of Eylea Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in Korea: Asan Hospital, Seoul National University Bundang Hospital, Samsung Seoul Hospital, and Severance Hospital. Alteogen has strengthened compet